Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
Identifieur interne : 001D37 ( Ncbi/Merge ); précédent : 001D36; suivant : 001D38Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
Auteurs : Raymond H. See [Canada] ; Martin Petric [Canada] ; David J. Lawrence [Canada] ; Catherine P Y. Mok [Canada] ; Thomas Rowe [États-Unis] ; Lois A. Zitzow [États-Unis] ; Karuna P. Karunakaran [Canada] ; Thomas G. Voss [États-Unis] ; Robert C. Brunham [Canada] ; Jack Gauldie [Canada] ; B Brett Finlay [Canada] ; Rachel L. Roper [États-Unis]Source :
- The Journal of general virology [ 0022-1317 ] ; 2008.
Descripteurs français
- KwdFr :
- Adénovirus humains (génétique), Animaux, Anticorps antiviraux (biosynthèse), Furets (immunologie), Furets (virologie), Humains, Modèles animaux de maladie humaine, Mâle, Poumon (anatomopathologie), Poumon (virologie), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation, Vaccins antiviraux (génétique), Vaccins antiviraux (pharmacologie), Vaccins atténués (génétique), Vaccins atténués (pharmacologie), Vaccins inactivés (pharmacologie), Vaccins synthétiques (génétique), Vaccins synthétiques (pharmacologie), Vecteurs génétiques, Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- anatomopathologie : Poumon, Syndrome respiratoire aigu sévère.
- biosynthèse : Anticorps antiviraux.
- génétique : Adénovirus humains, Vaccins antiviraux, Vaccins atténués, Vaccins synthétiques, Virus du SRAS.
- immunologie : Furets, Syndrome respiratoire aigu sévère, Virus du SRAS.
- pharmacologie : Vaccins antiviraux, Vaccins atténués, Vaccins inactivés, Vaccins synthétiques.
- virologie : Furets, Poumon, Syndrome respiratoire aigu sévère.
- Animaux, Humains, Modèles animaux de maladie humaine, Mâle, Syndrome respiratoire aigu sévère, Tests de neutralisation, Vecteurs génétiques.
English descriptors
- KwdEn :
- Adenoviruses, Human (genetics), Animals, Antibodies, Viral (biosynthesis), Disease Models, Animal, Ferrets (immunology), Ferrets (virology), Genetic Vectors, Humans, Lung (pathology), Lung (virology), Male, Neutralization Tests, SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Vaccines, Attenuated (genetics), Vaccines, Attenuated (pharmacology), Vaccines, Inactivated (pharmacology), Vaccines, Synthetic (genetics), Vaccines, Synthetic (pharmacology), Viral Vaccines (genetics), Viral Vaccines (pharmacology).
- MESH :
- chemical , biosynthesis : Antibodies, Viral.
- genetics : Adenoviruses, Human, SARS Virus, Vaccines, Attenuated, Vaccines, Synthetic, Viral Vaccines.
- immunology : Ferrets, SARS Virus, Severe Acute Respiratory Syndrome.
- pathology : Lung, Severe Acute Respiratory Syndrome.
- chemical , pharmacology : Vaccines, Attenuated, Vaccines, Inactivated, Vaccines, Synthetic, Viral Vaccines.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Ferrets, Lung, Severe Acute Respiratory Syndrome.
- Animals, Disease Models, Animal, Genetic Vectors, Humans, Male, Neutralization Tests.
Abstract
Although the 2003 severe acute respiratory syndrome (SARS) outbreak was controlled, repeated transmission of SARS coronavirus (CoV) over several years makes the development of a SARS vaccine desirable. We performed a comparative evaluation of two SARS vaccines for their ability to protect against live SARS-CoV intranasal challenge in ferrets. Both the whole killed SARS-CoV vaccine (with and without alum) and adenovirus-based vectors encoding the nucleocapsid (N) and spike (S) protein induced neutralizing antibody responses and reduced viral replication and shedding in the upper respiratory tract and progression of virus to the lower respiratory tract. The vaccines also diminished haemorrhage in the thymus and reduced the severity and extent of pneumonia and damage to lung epithelium. However, despite high neutralizing antibody titres, protection was incomplete for all vaccine preparations and administration routes. Our data suggest that a combination of vaccine strategies may be required for effective protection from this pathogen. The ferret may be a good model for SARS-CoV infection because it is the only model that replicates the fever seen in human patients, as well as replicating other SARS disease features including infection by the respiratory route, clinical signs, viral replication in upper and lower respiratory tract and lung damage.
DOI: 10.1099/vir.0.2008/001891-0
PubMed: 18753223
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A76
- to stream PubMed, to step Curation: 001A76
- to stream PubMed, to step Checkpoint: 001A19
Links to Exploration step
pubmed:18753223Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.</title><author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name><affiliation wicri:level="2"><nlm:affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Southern Research Institute, Birmingham, AL 35205</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name><affiliation wicri:level="2"><nlm:affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Southern Research Institute, Birmingham, AL 35205</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name><affiliation wicri:level="2"><nlm:affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Southern Research Institute, Birmingham, AL 35205</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Pathology and Molecular Medicine and Biology, McMaster University, Hamilton, ON L8N 3Z5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Pathology and Molecular Medicine and Biology, McMaster University, Hamilton, ON L8N 3Z5</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name><affiliation wicri:level="1"><nlm:affiliation>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name><affiliation wicri:level="2"><nlm:affiliation>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University, Greenville, NC 27834, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University, Greenville, NC 27834</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18753223</idno><idno type="pmid">18753223</idno><idno type="doi">10.1099/vir.0.2008/001891-0</idno><idno type="wicri:Area/PubMed/Corpus">001A76</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A76</idno><idno type="wicri:Area/PubMed/Curation">001A76</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A76</idno><idno type="wicri:Area/PubMed/Checkpoint">001A19</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A19</idno><idno type="wicri:Area/Ncbi/Merge">001D37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.</title><author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name><affiliation wicri:level="2"><nlm:affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Southern Research Institute, Birmingham, AL 35205</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name><affiliation wicri:level="2"><nlm:affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Southern Research Institute, Birmingham, AL 35205</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name><affiliation wicri:level="2"><nlm:affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Southern Research Institute, Birmingham, AL 35205</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name><affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea><wicri:noRegion>BC V5Z 4R4</wicri:noRegion></affiliation></author><author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Pathology and Molecular Medicine and Biology, McMaster University, Hamilton, ON L8N 3Z5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Pathology and Molecular Medicine and Biology, McMaster University, Hamilton, ON L8N 3Z5</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name><affiliation wicri:level="1"><nlm:affiliation>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name><affiliation wicri:level="2"><nlm:affiliation>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University, Greenville, NC 27834, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University, Greenville, NC 27834</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><series><title level="j">The Journal of general virology</title><idno type="ISSN">0022-1317</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviruses, Human (genetics)</term><term>Animals</term><term>Antibodies, Viral (biosynthesis)</term><term>Disease Models, Animal</term><term>Ferrets (immunology)</term><term>Ferrets (virology)</term><term>Genetic Vectors</term><term>Humans</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Male</term><term>Neutralization Tests</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (pathology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vaccines, Attenuated (genetics)</term><term>Vaccines, Attenuated (pharmacology)</term><term>Vaccines, Inactivated (pharmacology)</term><term>Vaccines, Synthetic (genetics)</term><term>Vaccines, Synthetic (pharmacology)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adénovirus humains (génétique)</term><term>Animaux</term><term>Anticorps antiviraux (biosynthèse)</term><term>Furets (immunologie)</term><term>Furets (virologie)</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Poumon (anatomopathologie)</term><term>Poumon (virologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (anatomopathologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (pharmacologie)</term><term>Vaccins atténués (génétique)</term><term>Vaccins atténués (pharmacologie)</term><term>Vaccins inactivés (pharmacologie)</term><term>Vaccins synthétiques (génétique)</term><term>Vaccins synthétiques (pharmacologie)</term><term>Vecteurs génétiques</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviruses, Human</term><term>SARS Virus</term><term>Vaccines, Attenuated</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénovirus humains</term><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Furets</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Ferrets</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Vaccins inactivés</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Vaccines, Attenuated</term><term>Vaccines, Inactivated</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Furets</term><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Ferrets</term><term>Lung</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Genetic Vectors</term><term>Humans</term><term>Male</term><term>Neutralization Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Mâle</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term><term>Vecteurs génétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the 2003 severe acute respiratory syndrome (SARS) outbreak was controlled, repeated transmission of SARS coronavirus (CoV) over several years makes the development of a SARS vaccine desirable. We performed a comparative evaluation of two SARS vaccines for their ability to protect against live SARS-CoV intranasal challenge in ferrets. Both the whole killed SARS-CoV vaccine (with and without alum) and adenovirus-based vectors encoding the nucleocapsid (N) and spike (S) protein induced neutralizing antibody responses and reduced viral replication and shedding in the upper respiratory tract and progression of virus to the lower respiratory tract. The vaccines also diminished haemorrhage in the thymus and reduced the severity and extent of pneumonia and damage to lung epithelium. However, despite high neutralizing antibody titres, protection was incomplete for all vaccine preparations and administration routes. Our data suggest that a combination of vaccine strategies may be required for effective protection from this pathogen. The ferret may be a good model for SARS-CoV infection because it is the only model that replicates the fever seen in human patients, as well as replicating other SARS disease features including infection by the respiratory route, clinical signs, viral replication in upper and lower respiratory tract and lung damage.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18753223</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1317</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>Pt 9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of general virology</Title><ISOAbbreviation>J. Gen. Virol.</ISOAbbreviation></Journal><ArticleTitle>Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.</ArticleTitle><Pagination><MedlinePgn>2136-2146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1099/vir.0.2008/001891-0</ELocationID><Abstract><AbstractText>Although the 2003 severe acute respiratory syndrome (SARS) outbreak was controlled, repeated transmission of SARS coronavirus (CoV) over several years makes the development of a SARS vaccine desirable. We performed a comparative evaluation of two SARS vaccines for their ability to protect against live SARS-CoV intranasal challenge in ferrets. Both the whole killed SARS-CoV vaccine (with and without alum) and adenovirus-based vectors encoding the nucleocapsid (N) and spike (S) protein induced neutralizing antibody responses and reduced viral replication and shedding in the upper respiratory tract and progression of virus to the lower respiratory tract. The vaccines also diminished haemorrhage in the thymus and reduced the severity and extent of pneumonia and damage to lung epithelium. However, despite high neutralizing antibody titres, protection was incomplete for all vaccine preparations and administration routes. Our data suggest that a combination of vaccine strategies may be required for effective protection from this pathogen. The ferret may be a good model for SARS-CoV infection because it is the only model that replicates the fever seen in human patients, as well as replicating other SARS disease features including infection by the respiratory route, clinical signs, viral replication in upper and lower respiratory tract and lung damage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>See</LastName><ForeName>Raymond H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petric</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Catherine P Y</ForeName><Initials>CPY</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zitzow</LastName><ForeName>Lois A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karunakaran</LastName><ForeName>Karuna P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Southern Research Institute, Birmingham, AL 35205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunham</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauldie</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Molecular Medicine and Biology, McMaster University, Hamilton, ON L8N 3Z5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finlay</LastName><ForeName>B Brett</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roper</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University, Greenville, NC 27834, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Gen Virol</MedlineTA><NlmUniqueID>0077340</NlmUniqueID><ISSNLinking>0022-1317</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000260" MajorTopicYN="N">Adenoviruses, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18753223</ArticleId><ArticleId IdType="doi">10.1099/vir.0.2008/001891-0</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Alabama</li><li>Caroline du Nord</li><li>Ontario</li></region><settlement><li>Hamilton (Ontario)</li></settlement><orgName><li>Université McMaster</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name></noRegion><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></country><country name="États-Unis"><region name="Alabama"><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name></region><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001D37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:18753223
|texte= Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:18753223" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |